iShares U.S. Pharmaceuticals ETF (IHE)
iShares U.S. Pharmaceuticals ETF $IHE Shares Bought by Bank of America Corp DE
Bank of America Corp DE boosted its position in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) by 2.8% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 456,606 shares of the company's stock after acquiring an additional 12,565 shares during
Will Generic Drug Tariffs Impact Pharma ETFs?
New U.S. tariffs on generic drugs could pressure drugmakers and influence pharmaceutical ETFs. Here's what investors should watch.
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?
Vanguard Health Care ETF offers a significantly lower expense ratio of 0.09% compared to 0.38% for iShares U.S. Pharmaceuticals ETF iShares U.S. Pharmaceuticals ETF has delivered higher total returns over the last five years but carries higher concentration risk with only 56 holdings Vanguard Health Care ETF provides broader sector diversification by covering the entire medical ecosystem while the iShares fund focuses strictly on drug manufacturers
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
IHE pays a meaningfully higher dividend yield than BBH. BBH offers more concentrated exposure with 25 holdings, compared to 56 for IHE.
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
iShares Global Healthcare ETF provides exposure to 110 international stocks, whereas iShares U.S. Pharmaceuticals ETF concentrates on 56 domestic companies iShares U.S. Pharmaceuticals ETF has higher concentration risk with its two largest holdings accounting for over 43.00% of the total portfolio iShares U.S. Pharmaceuticals ETF has outperformed on a one-year and five-year total return basis compared to iShares Global Healthcare ETF
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?
The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year returns but experienced a much steeper maximum drawdown over five years.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on May 1, 2006.
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?
The iShares U.S. Pharmaceuticals ETF (IHE) offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF (IBB). IBB offers broader diversification, with 248 holdings compared to just 56 for IHE.
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?
The iShares U.S. Pharmaceuticals ETF (IHE) charges a lower expense ratio and pays a higher dividend than the Invesco Pharmaceuticals ETF (PJP). IHE is heavily concentrated in its two largest holdings, while PJP spreads its bets more evenly across the sector's biggest names.
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors?
iShares U.S. Pharmaceuticals ETF offers a significantly higher dividend yield and lower volatility than State Street SPDR S&P Biotech ETF. While State Street SPDR S&P Biotech ETF delivered stronger 1-year returns, iShares U.S. Pharmaceuticals ETF showed much greater resilience with a shallower maximum drawdown.
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns
iShares U.S. Pharmaceuticals ETF provides more cost-efficient access to the healthcare sector with a lower expense ratio and a higher dividend yield Simplify Health Care ETF employs an active management strategy focused on innovation and donates its net profits to breast cancer research iShares U.S. Pharmaceuticals ETF has delivered higher total returns over the past year while maintaining lower price volatility than its peer
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.
Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?
The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway.
IHE: Healthcare Dashboard For May
The healthcare sector is undervalued based on historical averages, especially the healthcare equipment industry. iShares U.S. Pharmaceuticals ETF offers cap-weighted exposure to U.S. pharma, with 44% in Eli Lilly and Johnson & Johnson. Recent outperformance is notable: IHE is 27% ahead of XLV over the past 12 months.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund launched on May 1, 2006.
IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features
The iShares U.S. Pharmaceuticals ETF is led by Johnson & Johnson and Eli Lilly, two stocks whose earnings per share has nearly doubled over the last twelve months. Also in IHE's top ten holdings list are lower-growth but cheaper stocks like Pfizer. Overall, this balance results in a portfolio with very appealing growth-at-a-reasonable-price statistics. My calculations show that IHE's one-year estimated EPS growth rate is an exceptional 19.07%, while its forward P/E ratio sits at just 15.69x.
3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers
Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.
5 ETFs to Buy for January
5 ETFs to buy in January: momentum, small caps, chips, defense and healthcare shine as markets rally early in 2026 -- IWM, MTUM, SMH, XAR and IHE.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on May 1, 2006.